Annals of Oncology · 2024 · 62 citations · 19 references
MedicineOncologyPharmacotherapyBreast OncologyMolecular OncologyOncology PharmacotherapyBreast Cancer PharmacotherapyDose Adjustment In OncologyDose EscalationHer2-positive Breast CancerMalignant NeoplasmsMetastatic Breast CancerClinical Endpoint EvaluationHer2-positive Breast Cancer TherapyMenopausal StatusMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerOpen-label TrialsSafety Profile CharacterizationSerious Adverse Events
19
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text
Breast Cancer Statistics, 2022
Angela N. Giaquinto, Hyuna Sung, Kimberly D. Miller et al. · CA A Cancer Journal for Clinicians · 2022 · 2.4K citations · Full text
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text
Medicine, Oncology, Pharmacology +15